Your browser doesn't support javascript.
loading
Apelin-13 protects human neuroblastoma SH-SY5Y cells against amyloid-beta induced neurotoxicity: Involvement of anti oxidant and anti apoptotic properties.
Samandari-Bahraseman, Mohammad Rasoul; Elyasi, Leila.
Afiliación
  • Samandari-Bahraseman MR; Agronomy and Plant Breeding Group, Faculty of Agriculture, University of Lorestan, Khorramabad, Iran.
  • Elyasi L; Golestan Neuroscience Research Center (GNRC), Department of Anatomy, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
J Basic Clin Physiol Pharmacol ; 33(5): 599-605, 2022 Sep 01.
Article en En | MEDLINE | ID: mdl-33977683
OBJECTIVES: We investigated the effect of apelin-13 on the cellular model of AD, amyloid-ß (Aß) treated SH-SY5Y cells in rats. METHODS: The SH-SY5Y cells were pretreated with different doses of apelin-13 (1, 2.5, 5, and 10 µg/mL), half an hour before adding 50% Aß treatment. After 24 h, cells were evaluated for survival, oxidative stress, mitochondrial calcium release, caspase-3, and cytochrome c levels, compared to control group (beta-actin). Statistical analysis was performed by SPSS 16. RESULTS: Apelin-13 at the dose of 2.5 µg/mL protected against IC50 Aß (p<0.001). Apelin-13 at doses of 1, 2.5, and 5 µg/mL showed protective effects against the reactive oxygen species (ROS) produced by Aß (p<0.001). Apelin-13 at doses of 2.5 and 5 µg/mL reduced calcium release, caspase-3, and cytochrome c (all p<0.001). CONCLUSIONS: Apelin-13 prevented apoptosis, oxidative stress, and mitochondrial toxicity and can be a suitable option for treatment of AD. The appropriate treatment strategy for humans has to be investigated in future studies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Neuroblastoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Basic Clin Physiol Pharmacol Asunto de la revista: FARMACOLOGIA / FISIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Neuroblastoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Basic Clin Physiol Pharmacol Asunto de la revista: FARMACOLOGIA / FISIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Alemania